Non-interventional Observational Study With Pramipexole: Impact on Non-motor Symptoms in Parkinson's Disease
NCT00539214 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1192
Last updated 2013-11-01
Summary
* To compare the effect of pramipexole on depressive symptoms in early and advanced PD patients
* To evaluate the course of depressive symptoms measured with UPDRS Part I (mentation, behavior and mood) and with HADS-D under pramipexole treatment
* To investigate whether improvement of depressive symptoms is linked to improvement in motor function (UPDRS Part III)
Conditions
- Parkinson Disease
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Boehringer Ingelheim · Boehringer Ingelheim
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-03-31
- Primary Completion
- 2007-12-31
Countries
- Germany
Study Locations
More Related Trials
-
Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients
NCT00479401 ·Status: COMPLETED ·Phase: PHASE3
-
Observational Study in Parkinson's Disease of the Primary Care Population of Patients Treated With Pramipexole
NCT02236728 ·Status: COMPLETED
-
A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients
NCT00402233 ·Status: COMPLETED ·Phase: PHASE4
-
Overnight Switch Trial From Pramipexole IR to Pramipexole ER in Patients With Early Parkinson Disease
NCT00558025 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Early Parkinson's Disease
NCT01470859 ·Status: COMPLETED ·Phase: NA
-
Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease
NCT01673724 ·Status: COMPLETED ·Phase: PHASE4
-
A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period
NCT00560508 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
a PMS on Safety Profile of Pramipexole in Chinese Parkinson Disease Patients
NCT01361009 ·Status: COMPLETED
-
Pivotal Study in Advanced Parkinsons Disease Patients
NCT00466167 ·Status: COMPLETED ·Phase: PHASE3
-
Randomized Single-blind Placebo Controlled Comparative Trial of Pramipexole and Bromocriptine in Parkinson's Disease
NCT00240409 ·Status: COMPLETED ·Phase: PHASE3
-
Special Survey on Parkinson's Disease Patients Treated Long-term Use of Pramipexole
NCT00615914 ·Status: COMPLETED
-
Long-term Safety Study of Open-label Pramipexole ER in Patients With Advanced PD
NCT00577460 ·Status: COMPLETED ·Phase: PHASE3
-
Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).
NCT00601523 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's Disease
NCT02172573 ·Status: COMPLETED ·Phase: PHASE3
-
A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)
NCT00148486 ·Status: COMPLETED ·Phase: PHASE2
-
SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease
NCT00335166 ·Status: COMPLETED ·Phase: PHASE3
-
Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease
NCT02233023 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate in Patients With Parkinsonian Type Disorders
NCT03683225 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Special Survey on Parkinson's Disease (PD) Patients Without Concomitant Use of L-Dopa
NCT00613301 ·Status: COMPLETED
-
The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-Dopa
NCT03521635 ·Status: COMPLETED ·Phase: PHASE4
-
Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients
NCT01191944 ·Status: COMPLETED ·Phase: PHASE3
-
A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease
NCT01494532 ·Status: COMPLETED ·Phase: PHASE4
-
Impulse Control Disorders in Parkinson's Patients Treated With Pramipexole and Other Agents (DOMINION Study)
NCT00617019 ·Status: COMPLETED
-
Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's Disease
NCT02248220 ·Status: COMPLETED
-
Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease
NCT02157714 ·Status: COMPLETED ·Phase: PHASE1